ARCHIVES

Drug pricing: Amgen’s “bundling” violates antitrust laws, J&J claims in suit.

This article is from The Cancer Letter archive.

Vol. 31 No. 37 | October 14, 2005

Download PDF Visit The Full Archive

Related Articles

Auditor Raymond Weiss Finds “Incredible” Protocol Violations–26% Of Patients Were Ineligible For C225 Study

June 21, 2002

Abstracts Deadline For Cancer Congress Extended To Dec. 31

December 13, 1985

Committee Approves Concepts For Studies In Special Populations

December 11, 1987

Advisors Voted For Provenge Approval Despite Fundamental Flaws In Trials.

April 13, 2007

NIH Tells Grant Applicants One Resubmission Is Enough.

October 24, 2008

Survivorship Research RFA To Be Reissued; Biomedical Imaging Institute Names 10 to Advisory Council

November 29, 2002